148 related articles for article (PubMed ID: 17049181)
1. Administration of pegylated interferon-alpha-2a or -2b does not induce sickness behavior in Lewis rats.
Loftis JM; Wall JM; Pagel RL; Hauser P
Psychoneuroendocrinology; 2006 Nov; 31(10):1289-94. PubMed ID: 17049181
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human interferon-alpha does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats.
De La Garza R; Asnis GM; Pedrosa E; Stearns C; Migdal AL; Reinus JF; Paladugu R; Vemulapalli S
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jun; 29(5):781-92. PubMed ID: 15927336
[TBL] [Abstract][Full Text] [Related]
3. Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients.
Fumaz CR; Muñoz-Moreno JA; Ballesteros AL; Paredes R; Ferrer MJ; Salas A; Fuster D; Masmitjà E; Pérez-Alvarez N; Gómez G; Tural C; Clotet B
AIDS Care; 2007 Jan; 19(1):138-45. PubMed ID: 17129869
[TBL] [Abstract][Full Text] [Related]
4. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).
Reddy KR
Semin Liver Dis; 2004; 24 Suppl 2():33-8. PubMed ID: 15346244
[TBL] [Abstract][Full Text] [Related]
5. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis.
Sporea I; Danila M; Sirli R; Popescu A; Laza A; Baditoiu L
J Gastrointestin Liver Dis; 2006 Jun; 15(2):125-30. PubMed ID: 16802006
[TBL] [Abstract][Full Text] [Related]
6. Pegylated human interferon alpha 2a does not induce depression-associated changes in mice.
Kosel M; Bilkei-Gorzo A; Zawatzky R; Zimmer A; Schlaepfer TE
Psychiatry Res; 2011 Jan; 185(1-2):243-7. PubMed ID: 20580843
[TBL] [Abstract][Full Text] [Related]
7. Pegylated interferon monotherapy for chronic hepatitis C.
Heathcote J; Zeuzem S
Semin Liver Dis; 2004; 24 Suppl 2():39-45. PubMed ID: 15346245
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load.
Izumi N; Asahina Y; Kurosaki M; Uchihara M; Nishimura Y; Inoue K; Ueda K; Tsuchiya K; Hamano K; Itakura J; Miyake S
Intervirology; 2004; 47(2):102-7. PubMed ID: 15192274
[TBL] [Abstract][Full Text] [Related]
9. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
McHutchison J; Sulkowski M
J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
[TBL] [Abstract][Full Text] [Related]
10. The impact of pegylated-interferon α-2b on partial and massive hepatectomy model in rats.
Mori H; Shimada M; Ikegami T; Utsunomiya T; Imura S; Morine Y; Ikemoto T; Hanaoka J; Iwahashi S; Saito Y; Asanoma M; Yamada S; Miyake H
Hepatogastroenterology; 2012 Oct; 59(119):2300-4. PubMed ID: 23435145
[TBL] [Abstract][Full Text] [Related]
11. [Pegylated interferon alpha 2a in treating chronic hepatitis B patients].
Tian YL; Zhao W; Shen L; Liu W; Chang JB; Fang ZX; Yin WW; Wang L; Sun XB; Yang YJ
Zhonghua Gan Zang Bing Za Zhi; 2006 Nov; 14(11):806-10. PubMed ID: 17125604
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.
Asahina Y; Izumi N; Umeda N; Hosokawa T; Ueda K; Doi F; Tsuchiya K; Nakanishi H; Matsunaga K; Kitamura T; Kurosaki M; Uchihara M; Higaki M; Miyake S
J Viral Hepat; 2007 Jun; 14(6):396-403. PubMed ID: 17501760
[TBL] [Abstract][Full Text] [Related]
13. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
[TBL] [Abstract][Full Text] [Related]
14. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients.
Annemans L; Warie H; Nechelput M; Peraux B
Acta Gastroenterol Belg; 2004; 67(1):1-8. PubMed ID: 15149079
[TBL] [Abstract][Full Text] [Related]
15. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.
Bruno R; Sacchi P; Ciappina V; Zochetti C; Patruno S; Maiocchi L; Filice G
Antivir Ther; 2004 Aug; 9(4):491-7. PubMed ID: 15456079
[TBL] [Abstract][Full Text] [Related]
16. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C.
Baker DE
Rev Gastroenterol Disord; 2003; 3(2):93-109. PubMed ID: 12776006
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.
Reddy KR; Wright TL; Pockros PJ; Shiffman M; Everson G; Reindollar R; Fried MW; Purdum PP; Jensen D; Smith C; Lee WM; Boyer TD; Lin A; Pedder S; DePamphilis J
Hepatology; 2001 Feb; 33(2):433-8. PubMed ID: 11172346
[TBL] [Abstract][Full Text] [Related]
18. Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naive patients with chronic hepatitis C.
Bruno R; Sacchi P; Maiocchi L; Zocchetti C; Ciappina V; Patruno S; Filice G
Antivir Ther; 2005; 10(2):201-5. PubMed ID: 15865213
[TBL] [Abstract][Full Text] [Related]
19. Persistence with hepatitis C therapy in the Department of Veterans Affairs.
Iqbal SU; Cunningham F; Lee A; Miller DR; Li NC; Cheung R; Kazis L
J Clin Pharm Ther; 2008 Jun; 33(3):251-61. PubMed ID: 18452412
[TBL] [Abstract][Full Text] [Related]
20. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit.
Covic A; Maftei ID; Mardare NG; Ioniţă-Radu F; Totolici C; Tuţă L; Golea O; Covic M; Volovăţ C; Gusbeth-Tatomir P; Mircescu G
J Nephrol; 2006; 19(6):794-801. PubMed ID: 17173254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
